CarDon trying to adjust nursing homes to hospitals, insurers, patients
Family-run company is building nursing homes it thinks will be more attractive to residents and staff.
Family-run company is building nursing homes it thinks will be more attractive to residents and staff.
“Troll” is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
Compensation for Joe Swedish included $4.1 million in perks, such as $3.8 million he would have received in his previous job, $79,000 in relocation expenses, and $82,000 for his legal fees from contract negotiations.
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
A number of Indiana lawmakers – including both of the state’s U.S. senators – have advocated for the elimination of the tax, in part because the state is home to several key medical device manufacturers.
The 7 million target, thought to be out of reach by most experts, was in sight on a day that saw surging consumer interest as well as vexing computer glitches.
The last-minute flood of applicants in Indiana mirrored national trends as people sought to at least start the process Monday.
For now, at least, the year-to-year price increases of individual insurance under Obamacare look a lot like they did before Obamacare. That’s not a failure, but it’s not a success either.
Indiana University Health’s business deteriorated last year in nearly every area. But price hikes and a surge in outpatient visits to Indianapolis-area facilities mostly offset those problems.
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.’s first marketed product. The treatment would compete against Lilly’s Humalog. An FDA report tied the drug to a decline in lung function.
Like much else about Obama's health care law, the milestone comes with a caveat: The administration has yet to announce how many consumers actually closed the deal by paying their first month's premium.
When patients at Indianapolis-area hospitals pay their bills, they're not just funding their own health care. They're contributing to the care of Hoosiers in the rest of the state, too, especially care provided by hospital-employed physicians.
It was an exorcism of CNO’s legacy Conseco business recently that’s really put the proverbial color back in the faces of management and investors.
People who've started applying for health insurance but aren't able to finish before the March 31 enrollment deadline will get extra time, the Obama administration announced Tuesday.
Minors under 16 no longer can hop into a tanning bed at Indiana salons, even with parental supervision.
Two months before health insurers must submit rate proposals for 2015 to government regulators, WellPoint Inc. fired a surprising shot across their bow.
Franciscan Alliance, always the first to report its year-end financial results, put out numbers that show a real decline in profit from operations of 58 percent.
The health insurer predicted growth in government-funded health insurance programs would push revenue above $100 billion by 2018. That prompted investors to push WellPoint stock above $100 per share—an all-time high for the company.